Johns Hopkins ABX GuideBrand Names

Miltefosine

Kathryn Dzintars, Pharm.D., BCPS, Paul A. Pham, Pharm.D.
Miltefosine is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Johns Hopkins Guides

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Miltefosine is available under an expanded access IND form the CDC (770-488-7100) in the U.S. for the treatment of free-living ameba, including primary meningoencephalitis (PAM) caused by Naegleria fowleri and granulomatous amebic encephalitis (GAM) caused by Balamuthia mandrillaris and Acanthamoeba species.
  • Treatment of cutaneous, mucosal, and visceral leishmaniasis in patients >12 years of age.

NON-FDA APPROVED USES

  • Use in combination with voriconazole and terbinafine for the management of Scedosporium prolificans

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: April 5, 2016